DIA Europe 2019

Component Type: Session
Level: Intermediate

The key differentiator to AbbVie’s approach is the incorporation of safety science, behavioral science and health literacy to amplify the patient’s voice in the creation of products/programs to support informed decision making and promote safe use. Key Presenters: LINDA SCARAZZINI, MD, Vice President, PV CHERYL L RENZ, MD, Head, Benefit-Risk Management JAMES DUHIG, PHD, Director, Patient Integration AbbVie’s Patient Safety Teams – Benefit-Risk Management and Patient Integration – will present a unified session on patient centricity and then lead a participant discussion focused on the potential to bring innovative activities into patient safety organizations. In doing so, we will be able to show how AbbVie is demonstrating scientific leadership in patient focused drug development through research in patient and health professional decision-making, wearables, health literacy, and human-centered design to achieve a remarkable impact on the treatment, amelioration and elimination of disease. The presentation and ensuing discussion will showcase examples of incorporating the patient perspective into the design and implementation of innovative healthcare educational materials, applicable across global markets, to communicate essential risk information as a means to minimize key risks and ultimately optimize a product’s benefit-risk profile. The presentation will also demonstrate how a patient preference study uses hypothetical treatments with varied benefit-risk profiles to determine the relative importance of different benefit and risk attributes to patients and how this information can inform a company’s benefit-risk decision-making. In parallel, the discussion will ask participants to assess key successes achieved in combining behavioral science and benefit-risk management expertise and opportunities to similarly amplify the patient voice in their own organizations.